

Peptide Cancer Vaccine Industry Research Report 2024

<https://marketpublishers.com/r/P526EF079E92EN.html>

Date: April 2024

Pages: 128

Price: US\$ 2,950.00 (Single User License)

ID: P526EF079E92EN

Abstracts

Summary

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

According to APO Research, the global Peptide Cancer Vaccine market was valued at US\$ million in 2023 and is anticipated to reach US\$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.

North American market for Peptide Cancer Vaccine is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Peptide Cancer Vaccine is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Peptide Cancer Vaccine is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatix, Sellas, Imugene, VAXON Biotech and GenereX Biotechnology, etc. In 2023, the world's top three vendors

accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Peptide Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Cancer Vaccine.

The report will help the Peptide Cancer Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Peptide Cancer Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue (\$ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peptide Cancer Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Boston Biomedical

Ultimovacs

BrightPath Biotherapeutics

TapImmune

Immatics

Sellas

Imugene

VAXON Biotech

Generex Biotechnology

ISA Pharmaceuticals

OncoTherapy Science

Peptide Cancer Vaccine segment by Pipeline

ITK-1

GRN-1201

TPIV200

TPIV110

UV1

Galinpepimut-S

TARP 27-35

HER-Vaxx

Vx-001

Others

Peptide Cancer Vaccine segment by Application

Breast Cancer

Lung Cancer

Melanoma

Prostate Cancer

Others

Peptide Cancer Vaccine Segment by Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the

readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Peptide Cancer Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Peptide Cancer Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by pipeline, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

Contents

1 PREFACE

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 MARKET OVERVIEW

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Peptide Cancer Vaccine Market Size (2019-2030) & (US\$ Million)
 - 2.2.2 Global Peptide Cancer Vaccine Sales (2019-2030)
 - 2.2.3 Global Peptide Cancer Vaccine Market Average Price (2019-2030)
- 2.3 Peptide Cancer Vaccine by Pipeline
 - 2.3.1 Market Value Comparison by Pipeline (2019 VS 2023 VS 2030) & (US\$ Million)
 - 2.3.2 ITK-1
 - 2.3.3 GRN-1201
 - 2.3.4 TPIV200
 - 2.3.5 TPIV110
 - 2.3.6 UV1
 - 2.3.7 Galinpepimut-S
 - 2.3.8 TARP 27-35
 - 2.3.9 HER-Vaxx
 - 2.3.10 Vx-001
 - 2.3.11 Others
- 2.4 Peptide Cancer Vaccine by Application
 - 2.4.1 Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US\$ Million)
 - 2.4.2 Breast Cancer
 - 2.4.3 Lung Cancer
 - 2.4.4 Melanoma
 - 2.4.5 Prostate Cancer
 - 2.4.6 Others

3 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS

- 3.1 Global Peptide Cancer Vaccine Market Competitive Situation by Manufacturers (2019 Versus 2023)
- 3.2 Global Peptide Cancer Vaccine Sales (K Doses) of Manufacturers (2019-2024)
- 3.3 Global Peptide Cancer Vaccine Revenue of Manufacturers (2019-2024)
- 3.4 Global Peptide Cancer Vaccine Average Price by Manufacturers (2019-2024)
- 3.5 Global Peptide Cancer Vaccine Industry Ranking, 2022 VS 2023 VS 2024
- 3.6 Global Manufacturers of Peptide Cancer Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Peptide Cancer Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Peptide Cancer Vaccine, Date of Enter into This Industry
- 3.9 Global Peptide Cancer Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 MANUFACTURERS PROFILED

- 4.1 Boston Biomedical
 - 4.1.1 Boston Biomedical Company Information
 - 4.1.2 Boston Biomedical Business Overview
 - 4.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
 - 4.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
 - 4.1.5 Boston Biomedical Recent Developments
- 4.2 Ultimovacs
 - 4.2.1 Ultimovacs Company Information
 - 4.2.2 Ultimovacs Business Overview
 - 4.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
 - 4.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
 - 4.2.5 Ultimovacs Recent Developments
- 4.3 BrightPath Biotherapeutics
 - 4.3.1 BrightPath Biotherapeutics Company Information
 - 4.3.2 BrightPath Biotherapeutics Business Overview
 - 4.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
 - 4.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
 - 4.3.5 BrightPath Biotherapeutics Recent Developments

4.4 TapImmune

4.4.1 TapImmune Company Information

4.4.2 TapImmune Business Overview

4.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue and Gross Margin
(2019-2024)

4.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio

4.4.5 TapImmune Recent Developments

4.5 Immatix

4.5.1 Immatix Company Information

4.5.2 Immatix Business Overview

4.5.3 Immatix Peptide Cancer Vaccine Sales, Revenue and Gross Margin
(2019-2024)

4.5.4 Immatix Peptide Cancer Vaccine Product Portfolio

4.5.5 Immatix Recent Developments

4.6 Sellas

4.6.1 Sellas Company Information

4.6.2 Sellas Business Overview

4.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

4.6.4 Sellas Peptide Cancer Vaccine Product Portfolio

4.6.5 Sellas Recent Developments

4.7 Imugene

4.7.1 Imugene Company Information

4.7.2 Imugene Business Overview

4.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue and Gross Margin
(2019-2024)

4.7.4 Imugene Peptide Cancer Vaccine Product Portfolio

4.7.5 Imugene Recent Developments

4.8 VAXON Biotech

4.8.1 VAXON Biotech Company Information

4.8.2 VAXON Biotech Business Overview

4.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue and Gross Margin
(2019-2024)

4.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio

4.8.5 VAXON Biotech Recent Developments

4.9 Generex Biotechnology

4.9.1 Generex Biotechnology Company Information

4.9.2 Generex Biotechnology Business Overview

4.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue and Gross
Margin (2019-2024)

- 4.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
- 4.9.5 Generex Biotechnology Recent Developments
- 4.10 ISA Pharmaceuticals
 - 4.10.1 ISA Pharmaceuticals Company Information
 - 4.10.2 ISA Pharmaceuticals Business Overview
 - 4.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
 - 4.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
 - 4.10.5 ISA Pharmaceuticals Recent Developments
- 4.11 OncoTherapy Science
 - 4.11.1 OncoTherapy Science Company Information
 - 4.11.2 OncoTherapy Science Business Overview
 - 4.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
 - 4.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
 - 4.11.5 OncoTherapy Science Recent Developments

5 GLOBAL PEPTIDE CANCER VACCINE MARKET SCENARIO BY REGION

- 5.1 Global Peptide Cancer Vaccine Market Size by Region: 2019 VS 2023 VS 2030
- 5.2 Global Peptide Cancer Vaccine Sales by Region: 2019-2030
 - 5.2.1 Global Peptide Cancer Vaccine Sales by Region: 2019-2024
 - 5.2.2 Global Peptide Cancer Vaccine Sales by Region: 2025-2030
- 5.3 Global Peptide Cancer Vaccine Revenue by Region: 2019-2030
 - 5.3.1 Global Peptide Cancer Vaccine Revenue by Region: 2019-2024
 - 5.3.2 Global Peptide Cancer Vaccine Revenue by Region: 2025-2030
- 5.4 North America Peptide Cancer Vaccine Market Facts & Figures by Country
 - 5.4.1 North America Peptide Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
 - 5.4.2 North America Peptide Cancer Vaccine Sales by Country (2019-2030)
 - 5.4.3 North America Peptide Cancer Vaccine Revenue by Country (2019-2030)
 - 5.4.4 U.S.
 - 5.4.5 Canada
- 5.5 Europe Peptide Cancer Vaccine Market Facts & Figures by Country
 - 5.5.1 Europe Peptide Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
 - 5.5.2 Europe Peptide Cancer Vaccine Sales by Country (2019-2030)
 - 5.5.3 Europe Peptide Cancer Vaccine Revenue by Country (2019-2030)
 - 5.5.4 Germany
 - 5.5.5 France

5.5.6 U.K.

5.5.7 Italy

5.5.8 Russia

5.6 Asia Pacific Peptide Cancer Vaccine Market Facts & Figures by Country

5.6.1 Asia Pacific Peptide Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030

5.6.2 Asia Pacific Peptide Cancer Vaccine Sales by Country (2019-2030)

5.6.3 Asia Pacific Peptide Cancer Vaccine Revenue by Country (2019-2030)

5.6.4 China

5.6.5 Japan

5.6.6 South Korea

5.6.7 India

5.6.8 Australia

5.6.9 China Taiwan

5.6.10 Indonesia

5.6.11 Thailand

5.6.12 Malaysia

5.7 Latin America Peptide Cancer Vaccine Market Facts & Figures by Country

5.7.1 Latin America Peptide Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030

5.7.2 Latin America Peptide Cancer Vaccine Sales by Country (2019-2030)

5.7.3 Latin America Peptide Cancer Vaccine Revenue by Country (2019-2030)

5.7.4 Mexico

5.7.5 Brazil

5.7.6 Argentina

5.8 Middle East and Africa Peptide Cancer Vaccine Market Facts & Figures by Country

5.8.1 Middle East and Africa Peptide Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030

5.8.2 Middle East and Africa Peptide Cancer Vaccine Sales by Country (2019-2030)

5.8.3 Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2019-2030)

5.8.4 Turkey

5.8.5 Saudi Arabia

5.8.6 UAE

6 SEGMENT BY PIPELINE

6.1 Global Peptide Cancer Vaccine Sales by Pipeline (2019-2030)

6.1.1 Global Peptide Cancer Vaccine Sales by Pipeline (2019-2030) & (K Doses)

- 6.1.2 Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2019-2030)
- 6.2 Global Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
 - 6.2.1 Global Peptide Cancer Vaccine Sales by Pipeline (2019-2030) & (US\$ Million)
 - 6.2.2 Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2019-2030)
- 6.3 Global Peptide Cancer Vaccine Price by Pipeline (2019-2030)

7 SEGMENT BY APPLICATION

- 7.1 Global Peptide Cancer Vaccine Sales by Application (2019-2030)
 - 7.1.1 Global Peptide Cancer Vaccine Sales by Application (2019-2030) & (K Doses)
 - 7.1.2 Global Peptide Cancer Vaccine Sales Market Share by Application (2019-2030)
- 7.2 Global Peptide Cancer Vaccine Revenue by Application (2019-2030)
 - 7.2.1 Global Peptide Cancer Vaccine Sales by Application (2019-2030) & (US\$ Million)
 - 7.2.2 Global Peptide Cancer Vaccine Revenue Market Share by Application (2019-2030)
- 7.3 Global Peptide Cancer Vaccine Price by Application (2019-2030)

8 VALUE CHAIN AND SALES CHANNELS ANALYSIS OF THE MARKET

- 8.1 Peptide Cancer Vaccine Value Chain Analysis
 - 8.1.1 Peptide Cancer Vaccine Key Raw Materials
 - 8.1.2 Raw Materials Key Suppliers
 - 8.1.3 Peptide Cancer Vaccine Production Mode & Process
- 8.2 Peptide Cancer Vaccine Sales Channels Analysis
 - 8.2.1 Direct Comparison with Distribution Share
 - 8.2.2 Peptide Cancer Vaccine Distributors
 - 8.2.3 Peptide Cancer Vaccine Customers

9 GLOBAL PEPTIDE CANCER VACCINE ANALYZING MARKET DYNAMICS

- 9.1 Peptide Cancer Vaccine Industry Trends
- 9.2 Peptide Cancer Vaccine Industry Drivers
- 9.3 Peptide Cancer Vaccine Industry Opportunities and Challenges
- 9.4 Peptide Cancer Vaccine Industry Restraints

10 REPORT CONCLUSION

11 DISCLAIMER

List Of Tables

LIST OF TABLES

Table 1. Secondary Sources

Table 2. Primary Sources

Table 3. Market Value Comparison by Pipeline (2018 VS 2022 VS 2029) & (US\$ Million)

Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US\$ Million)

Table 5. Global Peptide Cancer Vaccine Volume and Revenue Market Size and CAGR of Manufacturers (2018 Versus 2022)

Table 6. Global Peptide Cancer Vaccine Sales (K Doses) of Manufacturers (2018-2023)

Table 7. Global Peptide Cancer Vaccine Sales Market Share by Manufacturers (2018-2023)

Table 8. Global Peptide Cancer Vaccine Revenue of Manufacturers (2018-2023)

Table 9. Global Peptide Cancer Vaccine Revenue Share by Manufacturers (2018-2023)

Table 10. Global Market Peptide Cancer Vaccine Average Price (USD/Dose) of Manufacturers (2018-2023)

Table 11. Global Peptide Cancer Vaccine Industry Ranking, 2021 VS 2022 VS 2023

Table 12. Global Manufacturers of Peptide Cancer Vaccine, Product Type & Application

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Peptide Cancer Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans)

Table 16. Boston Biomedical Company Information

Table 17. Boston Biomedical Business Overview

Table 18. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2018-2023)

Table 19. Boston Biomedical Peptide Cancer Vaccine Product Portfolio

Table 20. Boston Biomedical Recent Developments

Table 21. Ultimovacs Company Information

Table 22. Ultimovacs Business Overview

Table 23. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2018-2023)

Table 24. Ultimovacs Peptide Cancer Vaccine Product Portfolio

Table 25. Ultimovacs Recent Developments

Table 26. BrightPath Biotherapeutics Company Information

Table 27. BrightPath Biotherapeutics Business Overview

Table 28. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses),

Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2018-2023)

Table 29. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio

Table 30. BrightPath Biotherapeutics Recent Developments

Table 31. TapImmune Company Information

Table 32. TapImmune Business Overview

Table 33. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2018-2023)

Table 34. TapImmune Peptide Cancer Vaccine Product Portfolio

Table 35. TapImmune Recent Developments

Table 36. Immatix Company Information

Table 37. Immatix Business Overview

Table 38. Immatix Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2018-2023)

Table 39. Immatix Peptide Cancer Vaccine Product Portfolio

Table 40. Immatix Recent Developments

Table 41. Sellas Company Information

Table 42. Sellas Business Overview

Table 43. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2018-2023)

Table 44. Sellas Peptide Cancer Vaccine Product Portfolio

Table 45. Sellas Recent Developments

Table 46. Imugene Company Information

Table 47. Imugene Business Overview

Table 48. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2018-2023)

Table 49. Imugene Peptide Cancer Vaccine Product Portfolio

Table 50. Imugene Recent Developments

Table 51. VAXON Biotech Company Information

Table 52. VAXON Biotech Business Overview

Table 53. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2018-2023)

Table 54. VAXON Biotech Peptide Cancer Vaccine Product Portfolio

Table 55. VAXON Biotech Recent Developments

Table 56. Generex Biotechnology Company Information

Table 57. Generex Biotechnology Business Overview

Table 58. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2018-2023)

Table 59. Generex Biotechnology Peptide Cancer Vaccine Product Portfolio

Table 60. Generex Biotechnology Recent Developments

- Table 61. ISA Pharmaceuticals Company Information
- Table 62. ISA Pharmaceuticals Business Overview
- Table 63. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
- Table 64. ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
- Table 65. ISA Pharmaceuticals Recent Developments
- Table 66. OncoTherapy Science Company Information
- Table 67. OncoTherapy Science Business Overview
- Table 68. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
- Table 69. OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
- Table 70. OncoTherapy Science Recent Developments
- Table 71. Global Peptide Cancer Vaccine Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029
- Table 72. Global Peptide Cancer Vaccine Sales by Region (2018-2023) & (K Doses)
- Table 73. Global Peptide Cancer Vaccine Sales Market Share by Region (2018-2023)
- Table 74. Global Peptide Cancer Vaccine Sales by Region (2024-2029) & (K Doses)
- Table 75. Global Peptide Cancer Vaccine Sales Market Share by Region (2024-2029)
- Table 76. Global Peptide Cancer Vaccine Revenue by Region (2018-2023) & (US\$ Million)
- Table 77. Global Peptide Cancer Vaccine Revenue Market Share by Region (2018-2023)
- Table 78. Global Peptide Cancer Vaccine Revenue by Region (2024-2029) & (US\$ Million)
- Table 79. Global Peptide Cancer Vaccine Revenue Market Share by Region (2024-2029)
- Table 80. North America Peptide Cancer Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)
- Table 81. North America Peptide Cancer Vaccine Sales by Country (2018-2023) & (K Doses)
- Table 82. North America Peptide Cancer Vaccine Sales by Country (2024-2029) & (K Doses)
- Table 83. North America Peptide Cancer Vaccine Revenue by Country (2018-2023) & (US\$ Million)
- Table 84. North America Peptide Cancer Vaccine Revenue by Country (2024-2029) & (US\$ Million)
- Table 85. Europe Peptide Cancer Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)
- Table 86. Europe Peptide Cancer Vaccine Sales by Country (2018-2023) & (K Doses)

Table 87. Europe Peptide Cancer Vaccine Sales by Country (2024-2029) & (K Doses)

Table 88. Europe Peptide Cancer Vaccine Revenue by Country (2018-2023) & (US\$ Million)

Table 89. Europe Peptide Cancer Vaccine Revenue by Country (2024-2029) & (US\$ Million)

Table 90. Asia Pacific Peptide Cancer Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 91. Asia Pacific Peptide Cancer Vaccine Sales by Country (2018-2023) & (K Doses)

Table 92. Asia Pacific Peptide Cancer Vaccine Sales by Country (2024-2029) & (K Doses)

Table 93. Asia Pacific Peptide Cancer Vaccine Revenue by Country (2018-2023) & (US\$ Million)

Table 94. Asia Pacific Peptide Cancer Vaccine Revenue by Country (2024-2029) & (US\$ Million)

Table 95. Latin America Peptide Cancer Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 96. Latin America Peptide Cancer Vaccine Sales by Country (2018-2023) & (K Doses)

Table 97. Latin America Peptide Cancer Vaccine Sales by Country (2024-2029) & (K Doses)

Table 98. Latin America Peptide Cancer Vaccine Revenue by Country (2018-2023) & (US\$ Million)

Table 99. Latin America Peptide Cancer Vaccine Revenue by Country (2024-2029) & (US\$ Million)

Table 100. Middle East and Africa Peptide Cancer Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 101. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2018-2023) & (K Doses)

Table 102. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2024-2029) & (K Doses)

Table 103. Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2018-2023) & (US\$ Million)

Table 104. Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2024-2029) & (US\$ Million)

Table 105. Global Peptide Cancer Vaccine Sales by Pipeline (2018-2023) & (K Doses)

Table 106. Global Peptide Cancer Vaccine Sales by Pipeline (2024-2029) & (K Doses)

Table 107. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2018-2023)

Table 108. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2024-2029)

Table 109. Global Peptide Cancer Vaccine Revenue by Pipeline (2018-2023) & (US\$ Million)

Table 110. Global Peptide Cancer Vaccine Revenue by Pipeline (2024-2029) & (US\$ Million)

Table 111. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2018-2023)

Table 112. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2024-2029)

Table 113. Global Peptide Cancer Vaccine Price by Pipeline (2018-2023) & (USD/Dose)

Table 114. Global Peptide Cancer Vaccine Price by Pipeline (2024-2029) & (USD/Dose)

Table 115. Global Peptide Cancer Vaccine Sales by Application (2018-2023) & (K Doses)

Table 116. Global Peptide Cancer Vaccine Sales by Application (2024-2029) & (K Doses)

Table 117. Global Peptide Cancer Vaccine Sales Market Share by Application (2018-2023)

Table 118. Global Peptide Cancer Vaccine Sales Market Share by Application (2024-2029)

Table 119. Global Peptide Cancer Vaccine Revenue by Application (2018-2023) & (US\$ Million)

Table 120. Global Peptide Cancer Vaccine Revenue by Application (2024-2029) & (US\$ Million)

Table 121. Global Peptide Cancer Vaccine Revenue Market Share by Application (2018-2023)

Table 122. Global Peptide Cancer Vaccine Revenue Market Share by Application (2024-2029)

Table 123. Global Peptide Cancer Vaccine Price by Application (2018-2023) & (USD/Dose)

Table 124. Global Peptide Cancer Vaccine Price by Application (2024-2029) & (USD/Dose)

Table 125. Key Raw Materials

Table 126. Raw Materials Key Suppliers

Table 127. Peptide Cancer Vaccine Distributors List

Table 128. Peptide Cancer Vaccine Customers List

Table 129. Peptide Cancer Vaccine Industry Trends

Table 130. Peptide Cancer Vaccine Industry Drivers

Table 131. Peptide Cancer Vaccine Industry Restraints

Table 132. Authors List of This Report

List Of Figures

LIST OF FIGURES

Figure 1. Research Methodology

Figure 2. Research Process

Figure 3. Key Executives Interviewed

Figure 4. Peptide Cancer Vaccine Product Picture

Figure 5. Global Peptide Cancer Vaccine Revenue (US\$ Million), 2018 VS 2022 VS 2029

Figure 6. Global Peptide Cancer Vaccine Market Size (2018-2029) & (US\$ Million)

Figure 7. Global Peptide Cancer Vaccine Sales (2018-2029) & (K Doses)

Figure 8. Global Peptide Cancer Vaccine Average Price (USD/Dose) & (2018-2029)

Figure 9. ITK-1 Product Picture

Figure 10. GRN-1201 Product Picture

Figure 11. TPIV200 Product Picture

Figure 12. TPIV110 Product Picture

Figure 13. UV1 Product Picture

Figure 14. Galinpepimut-S Product Picture

Figure 15. TARP 27-35 Product Picture

Figure 16. HER-Vaxx Product Picture

Figure 17. Vx-001 Product Picture

Figure 18. Others Product Picture

Figure 19. Breast Cancer Product Picture

Figure 20. Lung Cancer Product Picture

Figure 21. Melanoma Product Picture

Figure 22. Prostate Cancer Product Picture

Figure 23. Others Product Picture

Figure 24. Global Peptide Cancer Vaccine Revenue Share by Manufacturers in 2022

Figure 25. Global Manufacturers of Peptide Cancer Vaccine, Manufacturing Sites & Headquarters

Figure 26. Global Manufacturers of Peptide Cancer Vaccine, Date of Enter into This Industry

Figure 27. Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2022

Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022

Figure 29. Global Peptide Cancer Vaccine Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Figure 30. Global Peptide Cancer Vaccine Sales by Region in 2022

Figure 31. Global Peptide Cancer Vaccine Revenue by Region in 2022

Figure 32. North America Peptide Cancer Vaccine Market Size by Country in 2022

Figure 33. North America Peptide Cancer Vaccine Sales Market Share by Country (2018-2029)

Figure 34. North America Peptide Cancer Vaccine Revenue Market Share by Country (2018-2029)

Figure 35. U.S. Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 36. Canada Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 37. Europe Peptide Cancer Vaccine Market Size by Country in 2022

Figure 38. Europe Peptide Cancer Vaccine Sales Market Share by Country (2018-2029)

Figure 39. Europe Peptide Cancer Vaccine Revenue Market Share by Country (2018-2029)

Figure 40. Germany Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 41. France Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 42. U.K. Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 43. Italy Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 44. Russia Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 45. Asia Pacific Peptide Cancer Vaccine Market Size by Country in 2022

Figure 46. Asia Pacific Peptide Cancer Vaccine Sales Market Share by Country (2018-2029)

Figure 47. Asia Pacific Peptide Cancer Vaccine Revenue Market Share by Country (2018-2029)

Figure 48. China Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 49. Japan Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 50. South Korea Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 51. India Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 52. Australia Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 53. China Taiwan Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 54. Indonesia Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 55. Thailand Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 56. Malaysia Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 57. Latin America Peptide Cancer Vaccine Market Size by Country in 2022

Figure 58. Latin America Peptide Cancer Vaccine Sales Market Share by Country (2018-2029)

Figure 59. Latin America Peptide Cancer Vaccine Revenue Market Share by Country (2018-2029)

Figure 60. Mexico Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 61. Brazil Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 62. Argentina Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 63. Middle East and Africa Peptide Cancer Vaccine Market Size by Country in 2022

Figure 64. Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Country (2018-2029)

Figure 65. Middle East and Africa Peptide Cancer Vaccine Revenue Market Share by Country (2018-2029)

Figure 66. Turkey Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 67. Saudi Arabia Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 68. UAE Peptide Cancer Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 69. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2018-2029)

Figure 70. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2018-2029)

Figure 71. Global Peptide Cancer Vaccine Price (USD/Dose) by Pipeline (2018-2029)

Figure 72. Global Peptide Cancer Vaccine Sales Market Share by Application (2018-2029)

Figure 73. Global Peptide Cancer Vaccine Revenue Market Share by Application (2018-2029)

Figure 74. Global Peptide Cancer Vaccine Price (USD/Dose) by Application (2018-2029)

Figure 75. Peptide Cancer Vaccine Value Chain

Figure 76. Peptide Cancer Vaccine Production Mode & Process

Figure 77. Direct Comparison with Distribution Share

Figure 78. Distributors Profiles

Figure 79. Peptide Cancer Vaccine Industry Opportunities and Challenges

I would like to order

Product name: Peptide Cancer Vaccine Industry Research Report 2024

Product link: <https://marketpublishers.com/r/P526EF079E92EN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P526EF079E92EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970